Clinical Trials Logo

Clinical Trial Summary

Meconium stained amniotic fluid increases the risk of maternal complications (e.g., dystocia, operative delivery, and postpartum endometritis) and neonatal complications (e.g., sepsis, admission to the neonatal intensive care unit [NICU], and meconium aspiration syndrome). The goal of the study is to compare between Azithromycin vs Placebo in cases of meconium stained amniotic fluid during the first stage of labor in multigravida women and their effect on maternal and neonatal outcomes.

Clinical Trial Description

Meconium stained amniotic fluid, a troublesome situation both for obstetrician and pediatrician, it is associated with high rates of caesarean section, perinatal morbidity and mortality. The rate of meconium-stained amniotic fluid varies from 12 to 20%.It is higher in underdeveloped countries.Our study design would be a prospective randomized trial. Consented, eligible pregnant women presenting during the first stage of labor at or more than 37 weeks of gestation with meconium stained amniotic fluid will be randomized to receive Azithromycin capsule (Zithromax, Pfizer) (250 mg / 12hrs on empty stomach for 3 days)(Group 1).Group 2 will be offered placebo capsules (manufactured in pharmacy department with the same shape, color and consistency as Azithromycin capsule for 3 days). ;

Study Design

Related Conditions & MeSH terms

NCT number NCT05118984
Study type Interventional
Source Cairo University
Status Completed
Phase Phase 4
Start date February 16, 2021
Completion date October 4, 2021

See also
  Status Clinical Trial Phase
Completed NCT01437228 - Does Preoperative Vaginal Preparation With Povidone-iodine Before Cesarean Delivery Reduce the Risk of Endometritis? Phase 4
Recruiting NCT04385680 - Chlorhexidine Vaginal Preparation for Reduction of Post-cesarean Endometritis and Sepsis Phase 1/Phase 2
Terminated NCT03478163 - Antibiotics During Intrauterine Balloon Tamponade Placement Phase 4
Not yet recruiting NCT03840889 - Secondary Postpartum Hemorrhage
Completed NCT03248297 - Antibiotic Prophlaxis for High-risk Laboring Women in Low Income Countries Phase 4